MedPath

Study on the efficacy and safety of Hydra valve

Not Applicable
Conditions
Health Condition 1: I350- Nonrheumatic aortic (valve) stenosis
Registration Number
CTRI/2024/05/067666
Lead Sponsor
Sahajanand Medical Technologies Limited (SMT)
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1. Patients affected by symptomatic severe aortic stenosis (NYHA class = II) eligible for TAVI procedure as per local Heart Team evaluation

2. Full understanding and willing to provide informed consent to study enrolment

Exclusion Criteria

1. Contraindications to TAVI (e.g., anatomically phenotypes, intracardiac mass, thrombus, vegetation, endocarditis)

2. Refusal to provide informed consent to study enrolment

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Primary safety endpoint: Cardiovascular mortality <br/ ><br>Primary performance endpoint: Device successTimepoint: 30 days
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath